The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives

Bibliography

• THONAR EJMA, MASUDA K, MANIC OURT D, KUETTNER KE: Structure and function of normal human adult articular cartilage. In: Osteoarthritis: clinical and experimental aspects. Reginster J-Y, Martel-Pelletier J, Pelletier J-P, Henrotin Y (Eds). Springer, Berlin Heidelberg (1999):1–19.
   Google Scholar
• ••This book describes in detail all aspects ofOA - from pathophysiology and diagnostics to medical, surgical and physical therapy and rehabilitation. It gives an overview of the current status of clinical and experimental aspects of OA.
   Google Scholar
• MARTEL-PELLETIER J, Di BATTISTA J, LAJEUNESSE D: Biochemical factors in joint articular tissue degradation. In: Osteoarthritis: clinical and experimental aspects. Reginster J-Y, Martel-Pelletier J, Pelletier J-P, Henrotin Y (Eds). Springer, Berlin Heidelberg (1999):156–188.
   Google Scholar
• •A thorough review of biochemical factors in OA.
   Google Scholar
• GOLDRING MB: The role of the chondrocyte in osteoarthritis. Arthritis Rheum. (2000) 9:1916–1927.
   Google Scholar
• •A excellent description of the key role played by chondrocytes in OA.
   Google Scholar
• NAITO K, TAKAHASHI M, KUSHIDA K et al.: Measurement of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in patients with knee osteoarthritis: comparison with generalized osteoarthritis. Rheumatology (1999) 38:510–515.
   PubMed Web of Science ®Google Scholar
• TETLOW LC, ADLAM DJ, WOOLLEY DE: Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage. Arthritis Rheum. (2001) 44(3):585–594.
   PubMedGoogle Scholar
• ••This work demonstrates the co-expressionof pro-inflammatory cytokines and MMPs and support the concept that cytokine-MMP associations contribute to the focal intrinsic process of cartilage degeneration.
   Google Scholar
• BLUTEAU G, CONROZIER T, MATHIEU P, VIGNON E, HERBAGE D, MALLEIN-GERIN F: Matrix metalloproteinase-1, -3, -13 and aggrecanase-1 and -2 are differentially expressed in experimental osteoarthritis. Biochim. Biophys. Acta. (2001) 1526:147–58.
   PubMed Web of Science ®Google Scholar
• TETLOW LC, WOOLEY DE: Expression of vitamin D receptors and matrix metalloproteinases in osteoarthritic cartilage and human articular chondrocytes in vitro. Osteoarthritis Cart.. (2001) 9: 423–431.
   PubMed Web of Science ®Google Scholar
• WALTER H, KAWASHIM A, NEBELUNG W NEUMANN W ROESSNER A: Immunohistochemical analysis of several proteolytic enzymes as parameters of cartilage degradation. Pathol. Res. Pract. (1998) 194(2):73–81.
   PubMedGoogle Scholar
• MILNER JM, ELLIOTT SF, CAWSTON TE: Activation of procollagenases is a key control point in cartilage collagen degradation. Arthritis Rheum. (2001) 44(9)2084–2096.
   Google Scholar
• ••This paper provides evidence for the role ofthe PA/plasmin cascade in the activation of pro-MMPs in cartilage.
   Google Scholar
• MURPHY G, COCKETT MI, STEPHENS PE, SMITH BJ, DOHERTY AJ: Stromelysin is an activator of procollagenase: a study with natural and recombinant enzymes. Biochem. 1 (1987) 248:265–268.
   PubMed Web of Science ®Google Scholar
• KNAUPER V, WILHELM SM, SEPERACK PK et al.: Direct activation of human neutrophil procollagenase by recombinant stromelysin. Biochem.j. (1993)295:581–586.
   PubMed Web of Science ®Google Scholar
• HE C, WILHEM SM, PENTLAND AP et al.: Tissue cooperation in a proteolytic cascade activating human intertitial collagenase. Proc. Natl. Acad. Sri. USA (1989) 86:2632–2636.
   PubMed Web of Science ®Google Scholar
• EECKOUT Y, VAES G: Further studies on the activation of procollagenase, the latent precursor of bone collagenase: effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation. Biochem. J. (1977) 166:21–31.
   PubMedGoogle Scholar
• TREAD WELL BV, PAVIA M, TOWLE CA, COOLEY VJ, MANKIN HJ: Cartilage synthesizes the serine proteinase inhibitor PAI-1: support for the involvement of serine proteases in cartilage remodeling. I Orthop. Res. (1991) 9:309–316.
   PubMedGoogle Scholar
• BELCHER C, FAWTHROP F, BUNNING R, DOHERTY M: Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Ann. Rheum. Dis. (1996) 55:230–236.
   PubMedGoogle Scholar
• MARTEL-PELLETIER J, FAURE MP, McCOLLUM R, MINEAU F, CLOUTIER JM, PELLETIER JP: Plasmin, Plasminogen activators and inhibitors in human osteoarthritic cartilage.J Rheumatol. (1991) 18:1863–1871.
   Google Scholar
• DEAN DD, MARTEL-PELLETIER J, PELLETIER JP, HOWELL DS, WOESSNER JF: Evidence for metalloproteinases and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. 1. Clin. Invest. (1989) 84:678–685.
   PubMed Web of Science ®Google Scholar
• •One of the first demonstrations of MMP/ MMPI imbalance in OA cartilage.
   Google Scholar
• CHUBINSKAYA S, KUETTNER KE, COLE AA: Expression of matrix metalloproteinases in normal and damaged articular cartilage from human knee and ankle joints. Lab. Invest. (1999) 79:1669–1699.
   PubMed Web of Science ®Google Scholar
• LARK MW, BAYNE EK, FLANAGAN J et al.: Aggrecan degradation in human cartilage. j Clin. Invest. (1997) 100:93–106.
   PubMed Web of Science ®Google Scholar
• BILLINGHURST RC, DAHLBERG L, IONESCU M et al.: Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. I. Clin. Invest. (1997) 99:1534–1545.
   PubMed Web of Science ®Google Scholar
• BAYLISS MT, HUTTON S, HAYWARD J, MACIEWICZ RA: Distribution of aggrecanase (ADAMts 4/5) cleavage products in normal and osteoarthritic human cartilage: the influence of age topography and zone of tissue. Osteoarthritis Cart. (2001) 9:553–560.
   PubMedGoogle Scholar
• •New insights into the distribution of ADAM-TS in normal and OA cartilage.
   Google Scholar
• MANICOURT D, FUJIMOTO N, OBATA K, THONAR EJM: Serum levels of collagenase, stromelysin-1, and TIMP-1. Arthritis Rheum. (1994) 37(12):1774–1783.
   PubMedGoogle Scholar
• LOHMANDER S, HOERRNER LA, LARK MW: Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum. (1993) 36(2):181–189.
   PubMedGoogle Scholar
• KOZACI LD, BUTTLE DJ, HOLLANDER AP: Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures. Arthritis Rheum. (1997) 40:164–174.
   PubMed Web of Science ®Google Scholar
• CHAMBERS MG, COX L, CHONG L et al.: Matrix metalloproteinases and aggrecanases cleave aggrecan in different zones of normal cartilage but cofocalize in the development of osteoarthritic lesions in STR/ort mice. Arthritis Rheum. (2001) 44:1544–1565.
   Google Scholar
• MARTEL-PELLETIER J, MC COLLUM R, FUJIMOTO N, OBATA K, CLOUTIER JM, PELLETIER JP: Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab. Invest. (1994) 70(6):807–831.
   PubMedGoogle Scholar
• OKADA Y, SHIMNEI M, TANAKA O et al.: Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab. Invest. (1992) 66(6):680–690.
   PubMedGoogle Scholar
• DAHLBERG L, BILLINGHURST RC, MANNER P et al.: Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum. (2000) 43(3):673–682.
   PubMedGoogle Scholar
• MITCHELL PG, MAGNA HA, REEVES LM et al.: Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. j Clin. Invest. (1996) 97:761–768.
   PubMed Web of Science ®Google Scholar
• CATTERRALL JB, CARRERE S, KOSHY PJT etal.: Synergic induction of matrix metalloproteinase 1 by interleukin-la and oncostatin M in human chondrocytes involves signal transducer and activator of transcription and activator protein 1 transcription factors via a novel mechanism. Arthritis Rheum. (2001) 44(10):2296–2310.
   Google Scholar
• •This study highlights a new mechanism for MMP-1 regulation in human chondrocytes.
   Google Scholar
• REBOUL P, PELLETIER JP, TARDIFF G, CLOUTIER JM, MARTEL-PELLETIER J: The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes: a role in osteoarthritis. j Clin. Invest. (1996) 97:2011–2019.
   PubMed Web of Science ®Google Scholar
• FERNANDES JC, MARTEL-PELLETIER J, LASCAU-COMAN V etal.: Collagenase-1 and collagenase-3 synthesis in normal and early experimental osteoarthritic canine cartilage: an immunohistochemical study. j Rheumatol. (1998) 25:1585–1594.
   Google Scholar
• •This paper describes the difference in the topographic distribution of collagenase-1 and collagenase-3 in OA.
   Google Scholar
• SHLOPOV BI, SMITH GN, COLE AA, HASTY KA: Differential patterns of response to doxycycline and transforming growth factor 131 in the down-regulation of collagenases in osteoarthritic and normal human chondrocytes. Arthritis Rheum. (1999) 42(4):719–727.
   PubMedGoogle Scholar
• TARDIF G, PELLETIER J-P, DUPUIS M, GENG C, CLOUTIER J-M, MARTEL-PELLETIER J: Collagenase 3 production by human osteoarthritic chondrocytes in response to growth factors and cytokines is a function of the physiologic state of the cells. Arthritis Rheum. (1999) 42 (6): 1147–1158.
   PubMedGoogle Scholar
• •This paper demonstrates the existence of two populations of chondrocytes with different patterns of response to cytokines.
   Google Scholar
• MENGSHOL JA, VINCENTI MP, COON CI, BARCHOWSKY A, BRINCKERHOFF CE: Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-jun n-terminal kinase, and nuclear factor kB. Arthritis Rheum. (2000) 43(4):801–811.
   PubMedGoogle Scholar
• •This study demonstrates for the first time, that p38, JNK and NficB are required for IL-1 induction of MMP–13.
   Google Scholar
• SANDY JD, FLANNERY CR, NEAME PJ, LOHMANDER SL: The structure of aggrecan fragments in human osteoarthritic synovial fluid: evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the g1u373-ala374 bond of the interglobular domain. j Clin. Invest. (1992) 89:1512–1516.
   PubMed Web of Science ®Google Scholar
• TANG BL: ADAMTS: a novel family of extracellular matrix proteases. Int. Biochem. Cell Biol. (2001) 33(1):33–44.
   PubMedGoogle Scholar
• CATERSON B, FLANNERY CR, HUGHES CE, LITTLE CB: Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol. (2000) 19(4)333–344.
   Google Scholar
• ••This paper is an excellent review on theneoepitopes generated during cartilage proteoglycan catabolism.
   Google Scholar
• TORTORELLA M, PRATTA M, LIU RQ eta].: The thrombospondin motif of aggrecanasel (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage. Biol. Chem. (2000) 275:25791–25797.
   Google Scholar
• SUGIMOTO K, TAKAHASHI M, YAMAMOTO Y, SHIMADA K, TANZAWA K: Identification of aggrecanase activity in medium of cartilage culture. Biochem. (1999) 126:449–455.
   Google Scholar
• VANKEMMELBEKE M, HOLEN I, WILSON AG et al.: Expression and activity of ADAMTS-5 in synovium. Eur. Biochem. (2001) 268:1259–1268.
   PubMedGoogle Scholar
• TORTORELLA MD, MALFAIT A-M, DECCICO C, ARNER E: The role of ADAM-T54 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cart. (2001) 9:539–552.
   PubMed Web of Science ®Google Scholar
• •This study gives new informations on the production of ADAM-TS by chondrocytes and their role in cartilage degradation.
   Google Scholar
• KASHIWAGI M, TORTORELLA M, NAGASE H, BREW K: TIMP-3 is a potent inhibitor of aggrecanase-1 (ADAM-T54) and aggrecanase-2 (ADAM-T55). J. Biol. Chem. (2001) 276(16):12501–12504.
   PubMed Web of Science ®Google Scholar
• KUNO K, OKADA Y, KAWASHIMA H et al.: ADAM-TS1 cleaves a cartilage proteoglycan, aggrecan. FEBS Lett. (2000) 478(3):241–245.
   PubMedGoogle Scholar
• FLANNERY CR, LITTLE CB, HUGHES CE, CATERSON B: Expression of ADAMTS homologue in articular cartilage. Biochem. Biophys. Res. Commun. (1999) 260:318–322.
   PubMedGoogle Scholar
• ABBASZADE I, LIU R-Q, YANG F et al.:Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. j Biol. Chem. (1999) 274(33):23443–23450.
   PubMed Web of Science ®Google Scholar
• BUTTNER FH, CHUBINSKAYA S, MARGERIE D et al.: Expression of membrane type 1 matrix metalloproteinase in human articular cartilage. Arthritis Rheum. (1997) 40:704–709.
   PubMed Web of Science ®Google Scholar
• OHUCHI E, IMAI K, FUJII Y, SATO H, SEIKI M, OKADA Y: Membrane type 1 matrix metalloproteinase digest interstitial collagens and other extracellular matrix macromolecules. j Biol. Chem. (1997) 272:2446–2451.
   PubMed Web of Science ®Google Scholar
• IMAI K, OHTA S, MATSUMOTO T et al.: Expression of membrane type 1 matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage. Am. J. Path. (1997) 151:153–159.
   Google Scholar
• •This paper details the role of MT1-MMP as MMPs activator.
   Google Scholar
• BOHM BB, AIGNER T, GEHRITZ A, BLOBEL CE KALDEN JR, BURKHARDT H.: Up-regulation of MD C15 (metargidin) messenger RNA in human osteoarthritic cartilage. Arthritis Rheum. (1999) 42(9):1946–1950.
   Google Scholar
• McKIE N, EDWARDS T, DALLAS DJ et al.: Expression of members of a novel membrane linked metalloproteinase family (ADAM) in human articular chondrocytes. Biochem. Biophys. Res. Commun. (1997) 230:335–339.
   PubMedGoogle Scholar
• BLACK RA, RAUCH CT, KOZLOSKY CJ et al.: A metalloproteinase desintegrin that releases tumour-necrosis factor a from cells. Nature (1997) 385:729–733.
   PubMed Web of Science ®Google Scholar
• PATEL IR, ATTUR MG, PATEL RN et al: TNF-a convertase enzyme from human arthritis-affected cartilage: isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF-a. j Immunol (1998) 160:4570–4579.
   PubMed Web of Science ®Google Scholar
• CHUBINSKAYA S, MIKHAIL R, DEUTSCH A, TINDAL MH: ADAM-10 protein is present in human articular cartilage primarily in the membrane form and is upregulated in osteoarthritis and in response to IL-la in bovine nasal cartilage. Histochem. Cytochem. (2001) 49:1165–1176.
   PubMed Web of Science ®Google Scholar
• KNAUPER V, LOPEZ-OTIN C, SMITH B, KNIGHT G, MURPHY G: Biochemical characterization of human collagenase-3. Biol. Chem. (1996) 271:1544–1550.
   Web of Science ®Google Scholar
• SATO H, TAKINO T, OKADA Y et al: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature (1994) 370:61–65.
   PubMed Web of Science ®Google Scholar
• TAKINO T, SATO H, SHINAGAWA A, SEIKI M: Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library: MT-MMPs form a unique membrane-type subclass in the MMP family. I Biol. Chem. (1995) 270:23013–23020.
   Google Scholar
• MATSUMOTO SI, KATOH M, SAITO S WATANABE T, MASUHO Y: Identification of soluble type of membrane-type matrix metalloproteinases-3 formed by alternatively spliced mRNA. Biochim. Biophys. Acta. (1997) 1354:159–170.
   PubMedGoogle Scholar
• PEI D: Identification and characterizationof the fifth membrane-type metalloproteinases MT5-MIVIP. j Biol. Chem. (1999) 274:8925–8932.
   PubMed Web of Science ®Google Scholar
• VELASCO G, CAL S, MERLOS-SUAREZ A et al.: Human MT6-matrix metalloproteinase: identification, progelatinase A activation and expression in brain tumors. Cancer Res. (2000) 60:877–882.
   PubMed Web of Science ®Google Scholar
• PEI D, WEISS SF: Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature (1995) 375:244–247.
   PubMed Web of Science ®Google Scholar
• WERB Z, MAINARDI CL, VATER CA et al.: Endogenous activation of latent collagenase by rheumatoid synovial cells: evidence for a role of plasminogen activator. N. Engl. J. Med. (1977) 296:1017–1023.
   PubMed Web of Science ®Google Scholar
• ANDREASEN PA, KJOLLER L, CHRISTENSEN L, DUFFY MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. Cancer (1997) 72:1–22.
   PubMed Web of Science ®Google Scholar
• SCHWAB W, GAVLIK JM, BEICHLER Tet al: Expression of the urokinase-type plasminogen activator receptor in human articular chondrocytes: association with caveolin and 13 1-integrin. Histochem. Cell. Biol. (2001) 115:317–323.
   PubMed Web of Science ®Google Scholar
• DEL ROSSO M, FIBBI G, PUCCI M, CERENIC MM: Antisense oligonucleotides against the urokinase receptor: a therapeutic strategy for of cell invasion in rheumatoid arthritis and cancer. Cilia. Exp. Rheumatol (1998) 16(4):389–393.
   PubMedGoogle Scholar
• •This paper gives new insights into the membrane activation of pro-uPA.
   Google Scholar
• FIBBI G, PUCCI M, SERNI U, CERENIC MM, DEL ROSSO M: Antisense targeting of the urokinase receptor blocks urokinase-dependent proliferation, chemoinvasion, and chemotaxis of human synovial cells and chondrocytes in vitro. Proc. Assoc. Am. Physicians (1998) 110(4):340–350.
   PubMedGoogle Scholar
• POLLANEN J, STEPHENS RW, VAHERI A: Direct plasminogen activation at the surface of normal and malignant cells. Adv. Cancer Res. (1991) 57:273–328.
   PubMed Web of Science ®Google Scholar
• CAMPBELL IK, LAST K, NOVAK U, LUND LR, HAMILTON JA: Recombinant human interleukin-linhibits plasminogen activator inhibitors-1 (PM-1) production by human articular cartilage and chondrocytes. Biochem. Biophys. Res. Commun. (1991) 174:251–257.
   PubMedGoogle Scholar
• LANG A, HORLER D, BAICI A: The relative importance of cysteine peptidases in osteoarthritis. j Rheumatol (2000) 27:1970–1979.
   PubMed Web of Science ®Google Scholar
• •Review on the implication of cyteine proteinases in OA.
   Google Scholar
• MARTEL-PELLETIER J, CLOUTIER JM, PELLETIER JP: Cathepsin B and cysteine protease inhibitors in human OA: effect of intra-articular steroid injections. Orthop. Res. (1990) 8:336–344.
   PubMed Web of Science ®Google Scholar
• KEYSZER G, REDLICH A, HAUPL T et al.: Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis. Arthritis Rheum. (1998) 41(8):1378–1387.
   PubMedGoogle Scholar
• DODDS RA, CONNORS JE, DRAKE FH, GOWEN M: Expression of cathepsin K messenger RNA in giants cells and their precursors in human osteoarhritis synovial tissues. Arthritis Rheum. (1999) 42(8):1588–1593.
   PubMedGoogle Scholar
• KOSTOULAS G, LANG A, NAGASE H, BAICI A: Stimulation of angiogenesis through cathepsin B inactivaion of the tissue inhibitors of matrix metalloproteinases. FEBS Lett. (1999) 455:286–290.
   PubMed Web of Science ®Google Scholar
• HANSEN T, PETROW PK, GAUMANN A et al.: Cathepsin B and its endogenous inhibitor cystatin C in rheumatoid arthritis synovium. I Rheumatol (2000) 27(4)859–865.
   Google Scholar
• LENARCIC B, GABRIJELCIC D, ROZMAN B, DROBNIC-KOSOROK M, TURK V: Human cathepsin B and cysteine proteinases inhibitors (CPIs) in inflammatory and metabolic disease. Biol. Chem. Hoppe. Seyler. (1988) 369:257–261.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ-BARRANTES S, TOTH M, BERNARDO MM et al.:Binding of active (57 Kda) membrane type-l-matrix metalloproteinase (MT1-MIVIP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MIV1P-2 activation. j Biol. Chem. (2000) 275:12080–12089.
   PubMed Web of Science ®Google Scholar
• APPARAILLY F, NOEL D, MILLET V et al.: Paradoxal effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis. Arthritis Rheum. (2001) 44: 1444–1454.
   PubMed Web of Science ®Google Scholar
• AMERICAN COLLEGE OF RHEUMATOLOGY SUBCOMMITEE ON OSTEOARTHRITIS GUIDELINES. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. Arthritis Rheum. (2000) 43(9):1905–1915.
   Google Scholar
• •American guidelines for the medical management of OA patients.
   Google Scholar
• GROUP FOR RESPECT OF ETHICS AND EXCELLENCE IN SCIENCE (GRESS): OSTEOARTHRITIS SECTION: Recommendations for the registration of drugs used in the treatment of osteoarthritis. Ann. Rheum. Dis. (1996) 55:552–557.
   PubMedGoogle Scholar
• •European recommendations for drug registration in the treament of OA.
   Google Scholar
• REGINSTER JY, DEROISY R, ROVATI L etal.: Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. The Lancet(2001) 357:251–256.
   Google Scholar
• ••The first randomised, controlled study demonstrating the structure-modifying effect of glucosamine sulfate in patients with knee OA.
   Google Scholar
• PAVELKA K, GATTEROVA J, OLEJAROVA M et al.: Glucosamine sulfate decreases progression of knee osteoarthritis in a long-term, randomized, placebo-controlled, independent, confirmatory trial. Arthritis Rheum. (2000) 43\(Suppl. 9):S384.
   Google Scholar
• PELLETIER JP, YARON M, HARAOUI Bet al.: Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo controlled trial. The diacerein study group. Arthritis Rheum. (2000) 43:2339–2348.
   Google Scholar
• APPELBOOM T, SCHERMANS J, VERBRUGGEN G, HENROTIN Y, REGINSTER J-Y: Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. Scam/. Rheumatol. (2001) 30:242–247.
   PubMed Web of Science ®Google Scholar
• JIMENEZ SA, DODGE GR: The effects of glucosamine sulfate (GS04) on human chondrocyte gene expression. Osteoarthritis Cart. (1997) 5(SA):72.
   Google Scholar
• SANDY JD, GAMETT D, THOMPSON V, VERSCHAREN C: Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 and retinoic acid can be inhibited by glucosamine. Biochein. (1998) 335:59–65.
   PubMed Web of Science ®Google Scholar
• BOUMEDIENE K, FELISAZ N, BOGDANOWICZ P, GALERA P, GUILLOU B, PUJOL J-P: Avocado/soya unsaponifiables enhance the expression of transforming growth factor 131 and 82 in cultured articular chondrocytes. Arthritis Rheum. (1999) 42(1):148–156.
   PubMedGoogle Scholar
• HENROTIN Y, LABASSE AH, JASPAR J- M etal.: Effects of three avocado/soybean unsaponifiable mistures on metalloproteainases, cytokines and prostaglandin E2 production by human articular chondrocytes. Clin. Rheumatol. (1998) 17:31–39.
   Google Scholar
• HENROTIN Y, SANCHEZ C, DEBERGH M, PICCARDIE N, GUILLOU B, REGINSTER J-Y: Long-term effects of avocado/soybean unsaponifiable on human chondrocytes metabolism. Osteoarthritis Cart. (2001) 9(Suppl. B):525.
   Google Scholar
• TAMURA, KOSAKA N, ISHIWA J, SATO T, NAGASE H, ITO A. Rhein, an active metabolite of diacerein, down-regulates the production of pro-matrix metalloproteinases-1, -2, -9 and -13 and upregulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular. Osteoarthritis Cart. (2001) 9:257–263.
   PubMed Web of Science ®Google Scholar
• CARNEY SL: Effect of diacetyl rhein on thedevelopment of experimental osteoarthritis. A biochemical investigation. Osteoarthritis Cart. (1996) 4:251–261.
   PubMedGoogle Scholar
• HWA S-Y, BURKHARDT D, LITTLE C, GHOSH P: The effects of orally administrated diacerein on cartilage and subchondral bone in ovine model of osteoarthritis. j Rheumatol. (2001) 28:825–843.
   PubMedGoogle Scholar
• PUJOL J-P, FELISAZ N, BOUMEDIENE K et al.: Effects of diacerein on biosynthesis activities of chondrocytes in culture. Biorheology (2000) 37:177–184.
   PubMedGoogle Scholar
• CAKE MA, REAS RA, GUILLOU B, GHOSH P: Modification of articular cartilage and subchondral bone pathology in an ovine meniscectomy model of osteoarthritis by avocado and soya unsaponifiables (ASU). Osteoarthritis Cart. (2000) 8:404–411.
   PubMed Web of Science ®Google Scholar
• YIP D, AHMAD A, KARAPETIS CS, HAWKINS CA, HARPER PG: Matrix metalloproteinase inhibitors: applications in oncology. Investig. New Drugs (1999) 17:387–399.
   PubMed Web of Science ®Google Scholar
• SHAW T, NIXON JS, BOTTOMLEY KM: Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis. Expert Opin. Investig. Dugs (2000) 9(7):1469–1478.
   PubMed Web of Science ®Google Scholar
• BROWN P: Ongoing trial with matrix metalloproteinase inhibitors. Expert Opin. Investig. Dugs (2000) 9(9):2167–2177.
   PubMed Web of Science ®Google Scholar
• SKILES JW, GONNELLA NC, JENG AY: The Design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem. (2201) 8(4):425–474.
   Google Scholar
• SHAH A, WOODRUFF M, AGARWAL V, LIU P, SUNDARESAN P: Pharmacokinetics, safety, and tolerability of BAY 12-9566 and nonsteroidal anti-inflammatory agents (naproxen, ibuprofen) during coadministration in patients with osteoarthritis. j Clin. Pharmacy]. (2001) 41:330–339.
   PubMed Web of Science ®Google Scholar
• LEFF RL: Clinical trials of a stromelysin inhibitor. Osteoarthritis, matrix metalloproteinase inhibition, cartilage loss, surrogate markers, and clinical implications. Ann. NY Acad. Sci. (1999) 878:201–207.
   Google Scholar
• BILLINGHURST RC, O'BRIEN K, POOLE AR, McILLWRAITH CW: Inhibitions of articular cartilage degradation in culture by a novel nonpeptide matrix metalloproteinase inhibitor. Ann. NY Acad. Li. (1999) 878:594–597.
   PubMedGoogle Scholar
• CHAU T, JOLLY G, PLYM JM et al.: Inhibition of of articular cartilage degradation in dog and guinea pig models of osteoarthritis by the stromelysin inhibitor, BAY 12–9566. Arthritis Rheum. (1998) 41 (Suppl. 9):5300.
   Google Scholar
• LEFF RA, ELIAS I, IONESCU M, REINER A, POOLE Al: Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12–9566. A novel matrix metalloproteinase inhibitor. Arthritis Rheum. (2000) 42 (Suppl. 9):5404.
   Google Scholar
• WANG M, LIU YE, GREENE G et al.: Oncogene (1997) 14: 2767.
   PubMedGoogle Scholar
• LOLLINI L, HARLER J, EUGUI E etal.: Disease modification by RS-130,830, a collagenase selective inhibitor in experimental osteoarthritis (OA). Arthritis Rheum. (1997) 40\(Suppl. 87):341.
   Google Scholar
• LEWIS EJ, BISHOP J, BOTTOMLEY KIVIK etal.: RO 32–3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br. Pharmacy]. (1997) 121:540–546.
   Google Scholar
• BREWSTER M, LEWIS EJ, WILSON KL, GREENHAM AK, BOTTOMLEY KMK: Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the str/ort mouse model of osteoarthritis. Arthritis Rheum. (1998) 41(9):1639–1644.
   PubMedGoogle Scholar
• WOOD N, AITKEN M, HARRIS S, KITCHENER S, McCLELLAND G, SHARP S: The tolerability and pharmacokinetics of the cartilage protective agent (RO 32-3555) in healthy male volunteers. Brit. j Cliii. Pharm. (1996) 42:676–677.
   Web of Science ®Google Scholar
• Roche puts arthritis drug on hold. Scrip (2000) 2528:20.
   Google Scholar
• NATCHUS MG, BOOKLAND RG, DE B et al.: Developement of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. Med. Chem. (2000) 43(26):4948–4963.
   Google Scholar
• AMIN AR, PATEL IR, ATTUR M et al.: A novel snake venom-like protease (SVP) from human arthritis-affected cartilage has properties of TNF-a convertase regulation in arthritis-affected cartilage. Arthritis Rheum. (Suppl.) (1997) 40:S78.
   Google Scholar
• FARAHAT NM, YANNI G, POSTON R, PANAYI GS: Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann. Rheum. Dis. (1993) 52:870–875.
   PubMed Web of Science ®Google Scholar
• JOUGLIN M, ROBERT C, VALETTE JP, GAVARD F, QUINTIN-COLONNA DENOIX JM: Metalloproteinases and tumor necrosis factor-a activities in synovial fluids of horse and correlation with articular cartilage alterations. Vet. Res. (2000) 31(5):507–515.
   PubMedGoogle Scholar
• MOO V, SIEPER J, HERZOG V, MULLER BM: Regulation of expression of cytokines and growth factors in osteoarthritic cartilage explants. Clic]. Rheumatol (2001) 20(5):353–358.
   PubMedGoogle Scholar
• CARON JP, FERNANDES JC, MARTEL-PELLETIER J et al.: Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: suppression of collagenase expression. Arthritis Rheum. (1996) 39:1535–1544.
   PubMed Web of Science ®Google Scholar
• VAN DE LOO FA, JOOSTEN LA, VAN LENT PL, ARNTZ OJ, VAN DEN BERG WB: Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen-and zymosan-induced arthritis. Arthritis Rheum. (1995) 38:164–172.
   PubMedGoogle Scholar
• PLOWS D, PROBERT L, GEORGOPOULOS S, ALEXOPOULOU L, KOLLIAS G: The role of tumour necrosis factor (TNF) in arthritis: studies in transgenic mice. Rheumatol Eur. (Suppl.) (1995) 2:51–54.
   Google Scholar
• CHIKANZA IC, ROUX-LOMBARD E DAYER JM, PANAYI GS: Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. OM Exp. Immune] (1993) 92:19–22.
   PubMed Web of Science ®Google Scholar
• WESTACOTT CI, BARAKAT AF, WOOD L et al.: Tumor necrosis factor a can contribute to focal loss of cartilage in osteoarthritis. Osteoarthritis Cart. (2000) 8(3):313–321.
   Google Scholar
• ELLIOTT MJ, MAINI RL, FELDMANN M etal.: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrasis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344:1105–1110.
   Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al: Treatment of rheumatoid arthritis with recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl. j Med. (1997) 337:141–147.
   PubMed Web of Science ®Google Scholar
• CONWAY JG, ANDREWS R, BEAUDET B et al.: Inhibition of tumor necrosis factor a (TNFa) production and arthritis in the rat by GW3333, a dual inhibitor of TNFa-converting enzyme and matrix metalloproteinases. Pharmacy]. Exp. Ther. (2001) 3:900–908.
   Google Scholar
• •This paper demonstrates that dual inhibitors of TACE and MMPs inhibit joint destruction in adjuvant arthritis model.
   Google Scholar